Stock Pulse
Thermo Fisher Scientific (TMO) demonstrated strong Q4 2024 financial performance with 5% revenue growth, reaching $11.4 billion, and substantial free cash flow exceeding $7.3 billion [1], [3], [6], [7]. The company recently acquired SOLV's Purification and Filtration business, strengthening its bioprocessing segment [1], [3]. Despite macroeconomic headwinds and declining COVID-19 testing demand impacting past stock performance [2], [5], TMO launched new products like the Krios 5 Cryo-TEM, driving investor optimism and a recent stock surge [4], [9]. While analysts are generally bullish on long-term growth, some suggest AI stocks may offer higher short-term returns [1], [3]. The company continues its commitment to customer-centric innovation and dividend growth [7], [9].